|
type 2 diabetes |
22 |
|
fatty liver disease |
20 |
|
diabetes mellitus |
16 |
|
coronary artery disease |
15 |
|
covid-19 |
15 |
|
sars-cov-2 |
15 |
|
thyroid function tests |
15 |
|
type 2 diabetes mellitus |
14 |
|
osteoporosis |
12 |
|
autoimmunity |
11 |
|
cardiovascular disease |
11 |
|
mafld (metabolic associated fatty liver disease) |
11 |
|
obesity |
11 |
|
overweight |
11 |
|
population based study |
11 |
|
thyroid gland |
11 |
|
thyroiditis |
11 |
|
adipocyte |
10 |
|
b-type natriuretic peptide |
10 |
|
cardiac troponin |
10 |
|
chinese |
10 |
|
fibroblast growth factor |
10 |
|
heart failure |
10 |
|
lipocalin-2 |
10 |
|
risk factor |
10 |
|
risk prediction |
10 |
|
cancer |
9 |
|
chronic hepatitis b |
9 |
|
diabetes |
9 |
|
liver fibrosis |
9 |
|
nucleoside analogues |
9 |
|
diabetic retinopathy |
8 |
|
genetic variants |
8 |
|
genome-wide association studies |
8 |
|
insr |
8 |
|
interferon beta-1b |
8 |
|
prediction model |
8 |
|
proliferative diabetic retinopathy |
8 |
|
sight-threatening diabetic retinopathy |
8 |
|
type 2 |
8 |
|
adipokine |
7 |
|
autoantibodies |
7 |
|
dpp4 inhibitor |
7 |
|
euthyroid sick syndromes |
7 |
|
fib-4 |
7 |
|
metabolic syndrome |
7 |
|
nfs |
7 |
|
post–acute covid-19 syndrome |
7 |
|
primary prevention |
7 |
|
prognosis |
7 |
|
sglt2 inhibitor |
7 |
|
adult |
6 |
|
alzheimer's disease |
6 |
|
asymptomatic |
6 |
|
cardiovascular diseases |
6 |
|
cohort profile // chinese |
6 |
|
crisps |
6 |
|
female |
6 |
|
general diabetes |
6 |
|
glycaemia |
6 |
|
glycated hemoglobin a |
6 |
|
hba1c variability |
6 |
|
high cardiovascular risk |
6 |
|
hip fractures |
6 |
|
humans |
6 |
|
hypoglycemia |
6 |
|
hypothyroidism |
6 |
|
immunotherapy |
6 |
|
middle aged |
6 |
|
neoplasms |
6 |
|
non-alcoholic fatty liver disease |
6 |
|
postmenopause |
6 |
|
prediabetes |
6 |
|
screening |
6 |
|
stress cardiac magnetic resonance |
6 |
|
survival |
6 |
|
thyroid diseases |
6 |
|
adipocyte fatty acid-binding protein |
5 |
|
adiponectin |
5 |
|
adverse cardiovascular outcomes |
5 |
|
anti-oxidant |
5 |
|
canagliflozin |
5 |
|
continuous glucose monitoring |
5 |
|
coronary heart disease |
5 |
|
dapagliflozin |
5 |
|
diacylglycerol |
5 |
|
drug repurposing |
5 |
|
elasticity imaging techniques |
5 |
|
endoscopic ultrasound |
5 |
|
fibrosis |
5 |
|
glucose-stimulated insulin secretion |
5 |
|
insulin resistance |
5 |
|
insulinoma |
5 |
|
lipidomic study |
5 |
|
lyso-phosphatidylcholine |
5 |
|
microvascular complications |
5 |
|
multiple endocrine neoplasia |
5 |
|
nephropathy |
5 |
|
non‐invasive |
5 |
|
paraganglioma |
5 |
|
pheochromocytoma |
5 |
|
radio frequency ablation |
5 |
|
risk assessment |
5 |
|
score |
5 |
|
sodium-glucose co-transporter 2 inhibitor |
5 |
|
succinate dehydrogenase |
5 |
|
treatment |
5 |
|
triacylglycerol |
5 |
|
vitamin a |
5 |
|
vitamin c |
5 |
|
vitamin e |
5 |
|
acth precursor |
4 |
|
afabp |
4 |
|
aged |
4 |
|
amiodarone - adverse effects |
4 |
|
anti-arrhythmia agents - adverse effects |
4 |
|
atrial fibrillation |
4 |
|
atypical femoral fractures |
4 |
|
bisphosphonates |
4 |
|
bone mineral density |
4 |
|
cardiovascular diseases - mortality |
4 |
|
cholesterol |
4 |
|
covid-19 vaccines |
4 |
|
covid‐19 |
4 |
|
cushing’s syndrome |
4 |
|
diabetes mellitus type 1 |
4 |
|
diabetes mellitus, type 2 |
4 |
|
dipeptidyl-peptidase iv inhibitors |
4 |
|
echocardiography |
4 |
|
ectopic acth syndrome |
4 |
|
exercise |
4 |
|
fractures, bone |
4 |
|
glucagon-like peptide-1 receptor agonists |
4 |
|
glycogenic hepatopathy |
4 |
|
graves' disease |
4 |
|
hip structure analysis |
4 |
|
hospitalization |
4 |
|
ischemic stroke |
4 |
|
liver function tests |
4 |
|
major adverse cardiovascular events |
4 |
|
male |
4 |
|
mortality |
4 |
|
multivariate analysis |
4 |
|
pancreatic tumor |
4 |
|
proteomics |
4 |
|
retrospective studies |
4 |
|
sodium glucose co-transporter 2 inhibitors |
4 |
|
sodium-glucose cotransporter 2 inhibitors |
4 |
|
sodium-glucose transporter 2 inhibitors |
4 |
|
statins |
4 |
|
stroke |
4 |
|
thyrotoxicosis - chemically induced |
4 |
|
trabecular bone score |
4 |
|
validation studies |
4 |
|
ventricular function, left - drug effects |
4 |
|
yolk sac tumor |
4 |
|
anti-infective agents - administration & dosage - adverse effects |
3 |
|
bone density |
3 |
|
chinese population |
3 |
|
ciprofloxacin - administration & dosage - adverse effects |
3 |
|
dry eye syndrome |
3 |
|
dyskinesia, drug-induced - etiology - therapy |
3 |
|
face |
3 |
|
fatty liver |
3 |
|
fibroblast growth factor 21 |
3 |
|
glucose control |
3 |
|
graves disease |
3 |
|
inflammation |
3 |
|
interferons |
3 |
|
machine learning algorithm |
3 |
|
metabolic outcomes |
3 |
|
personalized medicine |
3 |
|
post-acute covid-19 syndrome |
3 |
|
prevalence |
3 |
|
pyelonephritis - drug therapy |
3 |
|
risk stratification |
3 |
|
sglt2 inhibitors |
3 |
|
vaccines |
3 |
|
agranulocytosis |
2 |
|
antithyroid agents |
2 |
|
biomarkers |
2 |
|
china |
2 |
|
complication |
2 |
|
diet |
2 |
|
digeorge syndrome |
2 |
|
egfr equations |
2 |
|
gestational diabetes |
2 |
|
glucose intolerance |
2 |
|
granulocyte colony-stimulating factor |
2 |
|
hyperglycemia |
2 |
|
hypocalcemia |
2 |
|
iron deficiency |
2 |
|
metabolic steatohepatitis |
2 |
|
metabolomics |
2 |
|
non-alcoholic steatohepatitis |
2 |
|
non-invasive diagnosis |
2 |
|
personalized risk stratification |
2 |
|
prediction |
2 |
|
thalassemia |
2 |
